Evaluating GeneDx Holdings (WGS) Valuation After Recent Share Price Weakness

Simply Wall St

Tue, February 17, 2026 at 12:13 PM GMT+9 3 min read

In this article:

WGS

-0.57%

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

GeneDx Holdings: recent performance and business profile

GeneDx Holdings (WGS) has been on many investors’ radars after recent price moves, with the stock showing a 1 day return of about 1% and month and past 3 months returns in negative territory.

The company, headquartered in Stamford, Connecticut, focuses on genomics and provides genetic testing services, particularly in pediatric and rare disease diagnostics. It offers whole exome and genome sequencing, along with data and information services, as well as an AI based platform for NGS analysis, interpretation, and clinical reporting.

See our latest analysis for GeneDx Holdings.

At a share price of US$90.15, GeneDx’s recent trading has been soft, with a 30 day share price return of a 16.6% decline and a 90 day share price return of a 29% decline, even though the 3 year total shareholder return is more than 4x and the 1 year total shareholder return is 18.1%.

If GeneDx’s genomics story has caught your attention and you want to see what else is out there in AI powered healthcare, take a look at our 25 healthcare AI stocks for more potential ideas.

With GeneDx showing strong recent total returns but a weaker share price over the past few months, and trading at a large discount to analyst targets and intrinsic value estimates, is this a potential entry point, or is the market already pricing in future growth?

Most Popular Narrative: 47% Undervalued

GeneDx’s most followed narrative places fair value at about $170 per share, compared with the last close at $90.15, which is a wide gap for investors to weigh.

Rapid expansion into new and underpenetrated markets, including general pediatrics (driven by American Academy of Pediatrics guidelines), NICU, and additional pediatric specialties, positions GeneDx for substantial future volume and revenue growth as adoption of genomics as a frontline diagnostic tool accelerates.

Read the complete narrative.

Want to understand what kind of revenue curve and profit margins sit behind that valuation gap? The narrative leans on compound growth, richer margins, and a future earnings multiple that assumes GeneDx can behave more like a scaled platform than a niche tester. Curious how those moving parts combine into a $170 fair value line?

Story Continues  

Result: Fair Value of $170 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on GenomeDx Prenatal actually gaining traction and on reimbursement remaining supportive, and setbacks on either front could quickly challenge that $170 narrative.

Find out about the key risks to this GeneDx Holdings narrative.

Another View: Sales Multiple Tells A Different Story

While our DCF work points to GeneDx trading well below an estimated fair value, the sales multiple paints a tougher picture. At a P/S of 6.5x versus 1.3x for the US Healthcare industry and a 5.4x fair ratio, the stock carries clear valuation risk if sentiment cools.

For you, that raises a simple question: do you lean more on the long term cash flow story, or on what today’s revenue multiple is already asking you to pay?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:WGS P/S Ratio as at Feb 2026

Build Your Own GeneDx Holdings Narrative

If you see the numbers differently or simply prefer to work from your own assumptions, you can create a personalized GeneDx view in just a few minutes, Do it your way.

A great starting point for your GeneDx Holdings research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If GeneDx has sharpened your curiosity, do not stop here. The same tools can help you quickly scan the market for other compelling setups that fit your style.

Target quality at a discount by running through our 54 high quality undervalued stocks and see which companies currently line up with attractive fundamentals and pricing.

Prioritise resilience first with the 83 resilient stocks with low risk scores, so you can focus on businesses that score well on stability while you build out your watchlist.

Hunt for early opportunities using the screener containing 24 high quality undiscovered gems, where smaller names with solid numbers may not yet be widely followed.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include WGS.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info